L Parker Gregg1,2, S Susan Hedayati1. 1. Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center. 2. Renal Section, Medical Service, VA North Texas Healthcare System, Dallas, Texas, USA.
Abstract
PURPOSE OF REVIEW: It remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease. RECENT FINDINGS: Most studies of depression treatment were underpowered or uncontrolled. The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD. A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression showed improvement in depressive symptoms from baseline in both groups and a marginal benefit of sertraline over CBT that was of unclear clinical significance, given the lack of an active control group. SSRIs are associated with poor tolerability in clinical trials and serious adverse outcomes in large retrospective studies. SUMMARY: Although the data do not support unlimited use of SSRIs in patients with CKD or end-stage kidney disease, it is reasonable to initiate a cautious trial of sertraline while closely monitoring for depressive symptom improvement and adverse effects. CBT is a low-risk, possibly effective intervention to treat major depressive disorder in patients with kidney disease who have access to such treatments.
PURPOSE OF REVIEW: It remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease. RECENT FINDINGS: Most studies of depression treatment were underpowered or uncontrolled. The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD. A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression showed improvement in depressive symptoms from baseline in both groups and a marginal benefit of sertraline over CBT that was of unclear clinical significance, given the lack of an active control group. SSRIs are associated with poor tolerability in clinical trials and serious adverse outcomes in large retrospective studies. SUMMARY: Although the data do not support unlimited use of SSRIs in patients with CKD or end-stage kidney disease, it is reasonable to initiate a cautious trial of sertraline while closely monitoring for depressive symptom improvement and adverse effects. CBT is a low-risk, possibly effective intervention to treat major depressive disorder in patients with kidney disease who have access to such treatments.
Authors: Rajnish Mehrotra; Daniel Cukor; Mark Unruh; Tessa Rue; Patrick Heagerty; Scott D Cohen; Laura M Dember; Yaminette Diaz-Linhart; Amelia Dubovsky; Tom Greene; Nancy Grote; Nancy Kutner; Madhukar H Trivedi; Davin K Quinn; Nisha Ver Halen; Steven D Weisbord; Bessie A Young; Paul L Kimmel; S Susan Hedayati Journal: Ann Intern Med Date: 2019-02-26 Impact factor: 25.391
Authors: Daniel Cukor; Nisha Ver Halen; Deborah Rosenthal Asher; Jeremy D Coplan; Jeremy Weedon; Katarzyna E Wyka; Subodh J Saggi; Paul L Kimmel Journal: J Am Soc Nephrol Date: 2013-10-10 Impact factor: 10.121
Authors: S Turk; H Atalay; L Altintepe; I Güney; N Okudan; H Z Tonbul; H Gökbel; R Kücür; M Yeksan; A Yildiz Journal: Clin Nephrol Date: 2006-02 Impact factor: 0.975
Authors: N B Levy; M Blumenfield; C M Beasley; A K Dubey; R J Solomon; R Todd; A Goodman; R R Bergstrom Journal: Gen Hosp Psychiatry Date: 1996-01 Impact factor: 3.238
Authors: Nishank Jain; Madhukar H Trivedi; A John Rush; Thomas Carmody; Benji Kurian; Robert D Toto; Ravindra Sarode; S Susan Hedayati Journal: Contemp Clin Trials Date: 2012-10-22 Impact factor: 2.226
Authors: Suetonia C Palmer; Patrizia Natale; Marinella Ruospo; Valeria M Saglimbene; Kannaiyan S Rabindranath; Jonathan C Craig; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2016-05-23
Authors: Karin Friedli; Ayman Guirguis; Michael Almond; Clara Day; Joseph Chilcot; Maria Da Silva-Gane; Andrew Davenport; Naomi A Fineberg; Benjamin Spencer; David Wellsted; Ken Farrington Journal: Clin J Am Soc Nephrol Date: 2017-01-26 Impact factor: 8.237